SUCCESSFUL TREATMENT FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME IN A PUERPERA
Objective: to show the problems of differential diagnosis and treatment of atypical hemolytic-uremic syndrome in a 23-year-old patient.Results. Eculizumab (Soliris), (Alexon Pharmaceuticals Inc., USA) that is a glycosylated humanized monoclonal antibody to immunoglobulins (IgG2/4k) is shown to be ef...
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia
2016-01-01
|
| Collection: | Общая реаниматология |
| Sujets: | |
| Accès en ligne: | https://www.reanimatology.com/rmt/article/view/1500 |